Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.

Saved in:
Bibliographic Details
Title: Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Authors: Connolly RM; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.; Cancer Research @UCC, College of Medicine and Health, University College Cork, Ireland., Wang V; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, Massachusetts., Hyman DM; Memorial Sloan Kettering Cancer Center, New York, New York., Grivas P; University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington., Mitchell EP; Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania., Wright JJ; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Gray RJ; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, Massachusetts., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Patton DR; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, Maryland., Hamilton SR; City of Hope National Medical Center, Duarte, California., Wang J; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas., Wisinski KB; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas., O'Dwyer PJ; University of Pennsylvania, Philadelphia, Pennsylvania., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Apr 01; Vol. 30 (7), pp. 1273-1280.
Publication Type: Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-23-0633